The seventy-eight months follow-up and chemotherapy results of patients with germ cell testicular cancer GERM HUCRELI TESTIS KANSERLERINDE 78 AYLIK IZLEM VE KEMOTERAPI SONUCLARI
Bulletin of Gulhane Military Medical Academy, cilt.37, sa.1, ss.42-45, 1995 (Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 37 Sayı: 1
- Basım Tarihi: 1995
- Dergi Adı: Bulletin of Gulhane Military Medical Academy
- Derginin Tarandığı İndeksler: Scopus
- Sayfa Sayıları: ss.42-45
- Anahtar Kelimeler: Chemotherapy, Germ cell testicular cancer
- Sağlık Bilimleri Üniversitesi Adresli: Hayır
Özet
Between 1987 and 1994, 65 patients were diagnosed to have testicular cancer at Gulhane Military Medical Academy, department of medical oncology. Ten patients who have not undergone chemotherapy and 17 patients out of control were excluded. The mean age of 38 patients who were investigated was 21.89 ± 3.03 (range: 18-37). In patients who had chemotherapy; 13 % was stage A, 53 % was stage B and 34 % was stage C. Seven patients were seminoma and 31 patients were nonseminomatous testicular cancer. PVB regimen (cisplatin, vinblastin, bleomycin) was given in 31 patients, BEP (bleomycin, etopside, cisplatin) was given in 3 patients and various other combination chemotherapy regimens were given in 3 patients. The VIP regimen (etoposide, ifosfamide, cisplatin) as a salvage regimen was administered in 15 patients who relapsed after primary chemotherapy. Second-look laparotomy was done in five cases revealed, one mature teratoma, two metastatic carcinomas, one hyperplasia and a necrosis case. The maximum and median follow-ups were 78 and 14.49 months, respectively. The overall survival rate for 78 months follow-up, was 69.22 %. Severe side-effects were observed in 11 (29 %) patients. In conclusion, it may be said that our results are similar to that of other advanced centers.